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Abstract
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, yet disease-modifying
treatments do not currently exist. Rho-associated protein kinase (ROCK) was recently described as a novel
neuroprotective target in PD. Since alpha-synuclein (α-Syn) aggregation is a major hallmark in the pathogenesis of
PD, we aimed to evaluate the anti-aggregative potential of pharmacological ROCK inhibition using the isoquinoline
derivative Fasudil, a small molecule inhibitor already approved for clinical use in humans. Fasudil treatment significantly
reduced α-Syn aggregation in vitro in a H4 cell culture model as well as in a cell-free assay. Nuclear magnetic
resonance spectroscopy analysis revealed a direct binding of Fasudil to tyrosine residues Y133 and Y136 in the
C-terminal region of α-Syn. Importantly, this binding was shown to be biologically relevant using site-directed
mutagenesis of these residues in the cell culture model. Furthermore, we evaluated the impact of long-term Fasudil
treatment on α-Syn pathology in vivo in a transgenic mouse model overexpressing human α-Syn bearing the A53T
mutation (α-SynA53T mice). Fasudil treatment improved motor and cognitive functions in α-SynA53T mice as determined
by CatwalkTM gait analysis and novel object recognition (NOR), without apparent side effects. Finally,
immunohistochemical analysis revealed a significant reduction of α-Syn pathology in the midbrain of α-SynA53T mice
after Fasudil treatment. Our results demonstrate that Fasudil, next to its effects mediated by ROCK-inhibition, directly
interacts with α-Syn and attenuates α-Syn pathology. This underscores the translational potential of Fasudil as a
disease-modifying drug for the treatment of PD and other synucleinopathies.
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Introduction
In the coming decades the number of patients affected by
neurodegenerative disorders, including Parkinson’s disease
(PD), will inevitably increase [12]. Neurodegeneration in
PD is accompanied by the appearance of Lewy bodies,
intra-neuronal protein aggregates with α-synuclein (α-Syn)
as major component [4]. Initially established as histopatho-
logical marker for PD, aggregated α-Syn is now regarded as
key pathogenic agent [4]. Although α-Syn is a relatively
small molecule of 140 amino acids and can access different
cellular compartments [66], it is predominantly located in
presynaptic terminals, associated to membranous structures
like synaptic vesicles [4]. The discovery that point muta-
tions in α-Syn like A53T or A30P as well as α-Syn gene
multiplications facilitate the development of PD, underlines
the importance of α-Syn in this disease [28, 47, 52]. Fur-
thermore, α-Syn pathology is not restricted to dopamin-
ergic cells, but was also identified in neuronal cell
populations of the enteric nervous system and olfactory
bulb, explaining the variety of non-motor symptoms in
PD [48]. Several animal models using α-Syn mutants were
generated, either virus-mediated [38], or using transgenic
approaches. Transgenic mouse lines expressing human
α-Syn-A30P or -A53T develop motor and cognitive
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impairments, being in part similar to human PD symp-
toms, along with nigrostriatal degeneration and aggre-
gate pathology [16–19, 31, 40].
In previous studies in cell culture and animal models of
PD, Rho-associated protein kinase (ROCK) was identified
as novel molecular neuroprotective target [27, 50, 58, 59,
61]. Pharmacological ROCK inhibition protected against
MPTP toxicity, attenuating dopaminergic cell death and
increasing regenerative sprouting in vivo [59]. Since α-Syn
aggregation is a major step in the pathogenesis of PD, we
now evaluated the anti-aggregative potential of pharmaco-
logical ROCK inhibition using the isoquinoline derivative
Fasudil, a small molecule inhibitor already approved for
clinical use in humans in Japan [44].
In a cell culture model in H4 human neuroglioma cells
[42], we studied the effects of Fasudil treatment on α-Syn
aggregation. In a cell-free aggregation assay the direct
interaction of Fasudil and α-Syn was investigated and
nuclear magnetic resonance (NMR) spectroscopy was
then used to identify the binding sites of Fasudil on α-Syn.
Finally, a long-term treatment study in the α-SynA53T
mouse model [16] was performed to investigate the
impact of Fasudil application on α-Syn pathology in vivo.
Our results identify Fasudil as a drug with high transla-
tional potential as disease-modifying treatment for PD
and other synucleinopathies.
Materials and methods
Cell free α-Syn aggregation assay
Recombinant α-Syn was expressed and purified as de-
scribed previously [22]. Samples containing α-Syn were
diluted to a concentration of 100 μM in a 50 mM
HEPES (Sigma, Taufkirchen, Germany) buffer with
100 mM NaCl (Sigma) and 0.03 % NaN3 (Sigma) at
pH 7.4 in a 500 μl total volume and subsequently sub-
jected to aggregation-prone conditions (37 °C, ~300 rpm)
in low binding protein 1.5 ml Eppendorf tubes during at
least 14 days in the absence and presence of increasing
concentrations of Fasudil (LC Laboratories, Woburn, MA)
and Y-27632 (Tocris Bioscience, Bristol, UK) correspond-
ing to compound to protein ratios from 1:1 to 40:1. At dif-
ferent incubation times, a 10 μl aliquot of the sample was
mixed with 1 ml of a 100 mM ThT (Sigma) solution. Its
fluorescence emission was measured between 460 and
600 nm on a Varian Cary Eclipse fluorescence spectropho-
tometer (Agilent Technologies, Santa Clara, CA) with
excitation wavelength of 442 nm at 20 °C and with a 5 nm
excitation and emission slit. The averaged intensity values
of the maximum peak (~480 nm) were fitted to a
sigmoidal equation and presented as a function of time.
Electron microscopy of α-Syn fibrils
A solution containing protein was applied to glow-
discharged carbon coated grids and stained with 1 %
uranyl acetate (Sigma). Images were taken in a Philips
CM120 electron microscope (Philips, Amsterdam, The
Netherlands) at a defocus of 2.3 μm using a TemCam
224A slow scan CCD camera (TVIPS, Gauting, Germany).
NMR spectroscopy of α-Syn
Recombinant 15N-labeled α-Syn was expressed and
purified as described previously [22]. NMR samples
contained 0.1 mM 15N-labeled wild-type (wt) α-Syn in
50 mM HEPES buffer, 100 mM NaCl, pH 7.4 and 90 %
H2O/10 % D2O. NMR experiments were recorded on a
Bruker Avance 600 MHz spectrometer. The temperature
was set to 20 °C. Data processing was performed using
the software packages Topspin (Bruker, Billerica, MA)
and CCPN Analysis [64]. 15N-1H heteronuclear single
quantum coherence (HSQC) amide cross-peaks affected
during compound addition were identified by compari-
son of their chemical shift values with those of the same
cross-peaks in the data set of samples lacking the com-
pound. Perturbations in the chemical shift values for 1H
and 15N were calculated as [(Δδ1H)2 + (Δδ15N/10)2]1/2.
Plasmids
To investigate the impact of Fasudil treatment on α-Syn
aggregation, we used an aggregation model with co-
transfection of synphilin-1 (SYPH1) and carboxy-terminally
truncated αSyn.EGFP fusion protein (synT) in H4 human
neuroglioma cells in vitro, leading to the formation of intra-
cellular SYPH1/synT inclusions within 24 h after transfec-
tion. The corresponding plasmids pcDNA3.1/synT and
pcDNA3.1/V5-SYPH1 were described before [42].
Mutants of synT were generated by site-directed
mutagenesis using the following primers (5'-3'):
Y133A fw AAATGCCTTCTGAGGAAGGGGCTCAA
GACTACGAACCTGAA,
rev CTTCAGGTTCGTAGTCTTGAGCCCCTTCCT
CAGAAGGCATTT;
Y136A fw TTCTGAGGAAGGGTATCAAGACGCCG
AACCTGAAGCCGGTA,
rev CCCGCGGTACCGGCTTCAGGTTCGGCGTCT
TGATACCCTT;
Y133A/Y136A fw AAATGCCTTCTGAGGAAGGGG
CTCAAGACGCCGAACCTGAAG,
rev TACCGGCTTCAGGTTCGGCGTCTTGAGCCC
CTTCCTCAGAA.
Antibodies
The following primary antibodies were used: mouse
anti-α-Syn (BD610787, BD Biosciences, Franklin Lakes,
NJ), rabbit anti-V5 (ab9116, Abcam, Cambridge, UK),
mouse anti-α-Syn (LB509, Covance, Munich, Germany),
rabbit anti-TH (Zytomed, Berlin, Germany), rabbit anti-
TPH2 (ABN60, Millipore, Darmstadt, Germany), mouse
Tatenhorst et al. Acta Neuropathologica Communications  (2016) 4:39 Page 2 of 17
anti-NeuN (MAB377, Millipore) and mouse anti-β-
tubulin (Sigma, St- Louis, MO).
The following secondary antibodies were used: Cy2-
conjugated goat anti-mouse, Cy3-conjugated goat anti-
rabbit, Cy3-conjugated goat anti-mouse, Cy5-conjugated
goat anti-rabbit (all from Jackson Immuno Research, West
Grove, PA); horseradish peroxidase(HRP)-coupled goat
anti-mouse and HRP-coupled goat anti-rabbit (both from
Dianova, Hamburg, Germany).
Treatment, transfection, and immunocytochemistry of H4
cells
H4 human neuroglioma cells (HTB-148, ATCC, Manassas,
VA) were plated on poly-D-lysine (Sigma)-coated glass
cover slips at a density of 35,000/cm2 and pre-incubated
with 5 and 20 μM Fasudil or Y-27632 in DMEM (Gibco,
Karlsruhe, Germany) supplemented with 10 % fetal bovine
serum (PAA Laboratories, Pasching, Germany), 100 U/ml
Penicillin (Sigma), and 100 μg/ml Streptomycin (Sigma).
24 h later, cells were transfected with FuGENE HD
(Promega, Madison, WI) using wt or mutant synT and
SYPH1 plasmid DNA (total DNA 0.25 μg/cm2), and incu-
bated for additional 24 h with Fasudil or Y-27632. After
washing with PBS (Applichem, Darmstadt, Germany), cells
were fixed in PBS/4 % paraformaldehyde (PFA, Applichem)
for 10 min, permeabilized in PBS/0.5 % Triton X-100
(Applichem) for 20 min, and blocked in PBS/1.5 % normal
goat serum (NGS; PAA) for 1 h. Cells were incubated with
primary antibodies (mouse anti-α-Syn, 1:1000; rabbit anti-
V5, 1:5000) at 4 °C over night, washed in PBS and treated
with respective secondary antibodies (1:250) for 2 h
followed by staining with 2 μg/ml 4',6'-Diamidin-2-pheny-
lindol (Merck, Darmstadt, Germany) for 3 min and mount-
ing in Fluoromount G (Southern Biotech, Birmingham,
AL). Images were acquired using an Axioplan2 equipped
with AxioCam HRm camera and AxioVision SE64 Rel. 4.9
software (Carl Zeiss, Göttingen, Germany). Trans-
fected cells with and without inclusions from 9 im-
ages per experimental conditions of at least three
independent experiments were counted and compared
between groups.
Western blot analysis of H4 cells
H4 cells were lysed 24 h after transfection in RIPA
buffer consisting of 20 mM sodium phosphate (pH7.4;
Roth, Karlsruhe, Germany), 150 mM NaCl (Roth), 1 %
Triton X-100 (Roth), 0.5 % sodium deoxycholate
(Sigma), 0.5 % SDS (Roth), and protease inhibitors
(‘Complete tablets’, Roche, Basel, Switzerland). Briefly,
protein content of the samples was determined by BCA
assay (ThermoScientific, Rockford, IL, USA), and equal
amounts of protein (20 μg) were separated on a so-
dium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and blotted onto a nitrocellulose
membrane (Applichem). After blocking with 5 % nonfat
milk (Applichem) in Tris-buffered saline/Tween 20 (TBS-
T, Applichem) for 1 h membranes were incubated with
respective primary antibodies for 18 h at 4 °C in TBS-T
and 5 % milk. Finally, membranes were incubated with
corresponding horseradish peroxidase-coupled secondary
antibodies (1:4000 for 1 h at room temperature) and
chemiluminescence signal was visualized and quantified
using ECL (Immobilon Western, Millipore, Billerica, MA,
USA) and ChemiDoc XRS+ with Image Lab Software
(BIO-RAD, Hercules, CA, USA).
SEC-HPLC and dotblot analysis
H4 neuroglioma cells were collected 24 h after transfec-
tion in a phosphate buffer (1X PBS with 0.5 % TritonX-
100) freshly supplemented with protease inhibitor cocktail
(Roche, Mannheim, Germany) and centrifuged for 10 min
at 10,000 g. 2-3 mg of total protein in a maximum volume
of 500 μl was filtered using a 0.45 μm Spin-X centrifuge
filter before loading onto a Superose 6 (Superose 6 10/
300GL. GE Healthcare Life Science, Sweden) column and
subsequent high-performance liquid chromatography
(HPLC) (Äkta Purifier 10, GE Healthcare). The run was
performed with a flow rate of 0.5 ml/min and fractions of
500 μl were collected. For the dot blot assay, these fractions
were boiled at 95 °C for 10 min and centrifuged at 10,000 g
for 5 min. Afterwards they were loaded to a nitrocellulose
membrane with the following procedure being identical to
the previously described Western blot method.
Animal experiments
Animals were treated according to the regulations of the
local animal research council and legislation of the State
of Lower Saxony, Germany (33.19-42502-04-12/0884).
Heterozygous breeding couples of the transgenic mouse
strain B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J (short: α-
SynA53T) were bought from Jax Labs (J004479; Bar
Harbor, ME) and maintained at the Central Animal Care
Unit of the University Medicine Göttingen, Germany.
Offspring were genotyped using a qPCR protocol
according to Jax Labs’ instructions to discriminate
homozygous, heterozygous and wt animals. We selected
homozygous transgenic mice and wt littermates for our
experiments. Mice were housed in groups of five in indi-
vidually ventilated cages (IVC, Tecniplast, Hohenpeißen-
berg, Germany) under a 12 h light/12 h dark cycle with
free access to food and water. To monitor for changes in
weight, all mice were weighed once a week. From day 50
on mice were treated with Fasudil at a dosage of 10 mg
or 30 mg/kg bodyweight (bw) via the drinking water. A
daily drinking amount of 6 ml per animal was taken as a
basis and closely monitored to ensure an adequate
dosage as described before [58–60]. Treatment groups
were as follows: wildtype control (wt ctrl), α-SynA53T
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untreated control (A53T ctrl), α-SynA53T mice treated
with 10 mg/kg bw (A53T Fas10) and α-SynA53T mice
treated with 30 mg/kg bw (A53T Fas30). To assess
possible acute effects of Fasudil treatment, a separate co-
hort of α-SynA53T mice was treated with 30 mg/kg bw
Fasudil in the drinking water for 24 h, or with 20 mg/kg
bw Fasudil via oral gavage. Before each treatment, α-
SynA53T mice were tested on rotarod and Catwalk to obtain
a basic score. After 24 h Fasudil treatment via drinking
water, or 30 min after oral gavage, α-SynA53T mice were
tested again on rotarod and Catwalk, and the results
obtained were compared to baseline scores.
Blood of randomly selected mice was analyzed to moni-
tor for alterations of standard clinical chemistry and
hematology parameters due to Fasudil treatment. Ap-
proximately 200 μl blood were collected for hematological
analysis from the retrobulbar venous plexus and trans-
ferred to ethylene diamine tetra-acetic acid (EDTA) tubes,
the age of mice ranged from 200 to 700 days. For
biochemical analysis, about 1 ml blood was collected
under deep anesthesia with ketamine 200 mg/kg bw
(Medistar, Ascheberg, Germany) and xylazine 10 mg/kg
bw (Ecuphar, Greifswald, Germany) by heart puncture and
transferred to heparin tubes, mice were sacrificed immedi-
ately afterwards. Here, the age of mice ranged from 100 to
700 days. Blood samples were analyzed in the core facility
of the Clinical Chemistry Department of the University
Medicine Göttingen, Germany. Since α-SynA53T mice de-
velop a severe movement disorder starting with a paresis
of the hind limbs, earliest onset after about 8 months of
age [16], mice were closely monitored from day 220 on
regarding weight and motor behavior on the rotarod.
After clinical symptoms manifested, mice underwent
for the last time additional behavioral tests as de-
scribed below. To prevent animals from suffering
further paresis, mice were sacrificed after behavioral
tests were performed.
Rotarod
To measure motor balance and coordination, mice were
tested on an accelerated rotarod (rotarod for mice
47600, Ugo Basile, Comerio, Italy) ranging from 5 to
40 rpm within 5 min as described before [58, 59]. All
mice were pre-trained on the rotarod in order to reach a
stable performance. Rotarod test was performed after
100 d, 200 d, and from day 220 on twice a week, each
time in three sessions with an intertrial interval of
30 min to reduce stress and fatigue. Rotarod perform-
ance in all three runs was recorded and the average time
on the rotarod was evaluated. The continuous rotarod
testing twice a week from day 220 on was used to detect
the onset of clinical pathology described for this mouse
model [16] as early as possible for each animal. When
rotarod performance of a single mouse dropped below
50 % of its long term average, the respective animal was
termed as ‘disease onset’ and ultimately tested in
Catwalk gait analysis and novel object recognition test.
Catwalk gait analysis
Catwalk XT gait analysis system (Noldus, Wageningen,
The Netherlands) was used to monitor gait performance
of α-SynA53T mice and wt controls as described before
[50]. To address possible changes in gait performance
during disease progression, mice were tested before
possible clinical symptoms at 200 days, as well as at
‘disease onset’. During the test animals were placed in a
walkway of 4 cm width and videotaped from below. Foot-
prints were automatically detected by the Catwalk XT 10.0
software. Detection settings were as follows: camera gain
20; intensity threshold 0.10; max. allowed speed variation
60 %. Three compliant runs per animal were recorded and
means out of these runs were analyzed over treatment
groups with Catwalk XT 10.0 gait analysis software.
Novel object recognition test
To monitor for cognitive deficits in α-SynA53T mice, the
novel object recognition (NOR) test was performed as
described before [6]. Briefly, single mice were placed in
an arena of 48 × 35 cm for 3 min to habituate, and then
two identical objects were put into the arena to be
explored by the mouse for 5 min to familiarize. After a
10 min recovery in the home cage, mice were put back
into the arena for 5 min, where one of the familiar
objects had been changed to a novel one, which the
mouse had never seen before. During the test mice were
videotaped, and the time spent with familiar and novel
object, as well as general movement parameters (mobility,
velocity, distance moved) were detected by Ethovision XT
8.5 software (Noldus; Fig 6a, b). The discrimination ratio
(time spent with novel object/time spent with both ob-
jects) was calculated as described before [6] and compared
between the treatment groups.
Immunohistochemistry
Mice were sacrificed by exposure to carbon dioxide and
directly afterwards perfused transcardially with PBS,
followed by 4 % paraformaldehyde (PFA; Applichem) in
PBS (pH 7.4). Brains were dissected, post-fixed in PFA
overnight at 4 °C, and finally embedded into paraffin.
Brains were coronally sectioned into 5 μm slices,
mounted on slides and deparaffinized by xylene (Sigma)
treatment for 2x 10 min, followed by a descending etha-
nol (EtOH) row (2x 3 min 100 % EtOH (Applichem),
96 %, 90 %, 70 %, 50 % EtOH for 3 min each). For
immunohistochemistry, sections were incubated for
30 min in citrate buffer (10 mM citric acid (Sigma),
0.05 % Tween 20 (Applichem), pH 6.0 at 80 °C. After
cooling down, sections were either treated with 10 μg/
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ml proteinase K (PK, Applichem) in PBS at 55 °C for
12 min to quantify α-Syn pathology, or just washed with
PBS, followed by incubation in 0.1 g sudan black (Appli-
chem) per 100 ml 70 % EtOH. After rinsing with water
and PBS washing, sections were incubated for 20 min in
25 mM glycine (Applichem) in PBS. Afterwards sections
were blocked for 1.5 h in a solution of 10 % normal
horse serum (NHS, PAA), 5 % bovine serum albumin
(BSA, Applichem), 0.3 % Triton-X 100 (Applichem) and
25 mM glycine in PBS. First antibodies against α-Syn
(1:500, Covance), TH (1:1000, Zytomed), TPH2 (1:100,
Millipore) or NeuN (1:100, Millipore) diluted in blocking
solution were applied to the sections and incubated in a
wet chamber over night at 4 °C. After 3x washing in PBS
respective secondary antibodies were used (goat anti-
mouse Cy3, 1:250; goat anti-rabbit Cy5, 1:250) and incu-
bated for 1.5 h at room temperature. After 3x washing
in PBS, cell nuclei were counterstained with DAPI
(Sigma) for 2 min, after final washing in PBS sections
were dried and embedded with Mowiol (Sigma). From
each brain region, namely red nucleus (RN), substantia
nigra (SN) and dorsal raphe nucleus (DR), three to five
sections were stained and evaluated by a blinded investi-
gator. Cells with proteinase-K resistant α-Syn aggregates
as a marker for α-Syn pathology, as well as neuronal cells
were counted in the respective brain regions. The means
of at least three independent stainings were calculated and
normalized to the respective region’s area as determined
by immunohistochemical staining against NeuN for the
RN, TH for the SN and TPH2 for the DR.
Statistical analysis
Statistical analyses were conducted using Kyplot software
(Version 2.0, KyensLab Incorporated, Tokyo, Japan).
Comparisons of two groups were done by unpaired
Student’s T-Test, multiple group comparisons by one-way
ANOVA with Dunnett post-hoc test. The statistical test
and number of in vitro experiments or animals used for
analysis is indicated in each figure legend. Data are pre-
sented as mean ± SD or mean ± SEM, as indicated. Differ-
ences were considered significant when p < 0.05 (*p < 0.05;
**p < 0.01; ***p < 0.001; n.s. = not significant).
Results
Fasudil alters synT aggregation in the H4 aggregation
model
Co-transfection of synT and SYPH1 leads to formation
of intracellular inclusions within 24 h after transfec-
tion [30, 42]. Treatment with Fasudil, beginning 24 h
before transfection, reduced the number of transfected
H4 cells with inclusions in a dose-dependent manner
within 24 h (Fig. 1a, b).
As compared to untreated control (ctrl: 21.8 ± 1.95 %),
treatment with 20 μM Fasudil significantly reduced the
percentage of cells with inclusions by almost 50 %
(Fas20: 12.8 ± 0.82 %, p = 0.007, ANOVA with Dunnett
post-hoc test) (Fig. 1c). Western blot analysis of protein
lysates collected 24 h after transfection showed that
Fig. 1 Fasudil treatment significantly reduces synT aggregation in
H4 cells in vitro. a H4 neuroglioma cells were seeded in the
presence or absence of Fasudil and 24 h later transfected with
plasmids encoding for synT and SYPH1. 24 h after transfection,
cultures were investigated by immunocytochemistry (ICC), Western
blot (WB) and size-exclusion-chromatography-HPLC (SEC-HPLC). b
ICC of synT and SYPH1 in H4 cells 24 h after transfection, treated with
different Fasudil concentrations. Scale bar: 50 μm. c Quantification
of transfected H4 cells with inclusions 24 h after transfection and
treatment with different Fasudil concentrations. **p < 0.01, ANOVA
with Dunnett post-hoc test, n = 4. d WB analysis of H4 protein lysates
24 h after transfection treated with different Fasudil concentrations
revealed no significant differences in protein levels between groups.
e Quantification of dot-blot analysis against α-Syn after SEC-HPLC
fractionation of H4 protein lysates 24 h after Fasudil treatment.
Fractions were grouped according to gel filtration standard
components. Fraction 1: >670 kDa, fraction 2: 670-158 kDa, fraction
3: 158-17 kDa, fraction 4: <17 kDa. Data are given as mean ± SEM.
*p < 0.05, T-Test, n(ctr): 8; n(Fas20): 6
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Fasudil treatment did not significantly change synT
protein levels (Fig. 1d). In comparison, Y-27632 treat-
ment did not have any significant effect on the number
of transfected H4 cells with inclusions (Additional file 1:
Figure S1). Therefore, a concentration of 20 μM Fasudil
was used in the ongoing cell culture experiments.
SEC-HPLC was used to separate protein fractions
according to size with regard to gel filtration standard
components. Protein fractions were collected and analyzed
by dot-blot against synT. Fasudil treatment significantly
decreased the number of high molecular weight aggregates,
and simultaneously increased the protein amount in the
fraction <17 kDa (fraction 1 > 670 kDa: 44.7 ± 4.62 %
vs. 32.1 ± 4.55 %, p = 0.02, T-Test; fraction 2 670-158 kDa:
39.1 ± 2.93 % vs. 44.6 ± 4.43 %; fraction 3 158-17 kDa:
6.6 ± 0.76 % vs. 7.5 ± 1.32 %; fraction 4 < 17 kDa: 9.5 ±
1.01 % vs. 15.7 ± 2.68 %, p = 0.03, T-Test), possibly suggest-
ing a shift of aggregated synT to monomeric synT after
Fasudil treatment (Fig. 1e).
Fasudil attenuates α-Syn aggregation by direct C-terminal
interaction
α-Syn is a natively unfolded protein that upon exposure to
aggregation-prone conditions forms amyloid fibrils that
are reactive with Thioflavin T (ThT) and are visible by
electron microscopy (EM). To probe the influence of Fas-
udil on the aggregation kinetics of α-Syn, we monitored
the change in ThT fluorescence of samples both in the
presence and absence of Fasudil as well as the structurally
unrelated ROCK-inhibitor Y-27632, a 4-aminopyridine
derivative (Fig. 2a). The data show a clear delay in α-Syn
aggregation in presence of Fasudil, increasing the lag
phase from ~2.5 to ~8 days. Comparison of Fasudil (Fas) to
control (ctrl) after 9 days revealed a significant difference
(ctrl: 1.01 ± 0.16, n = 3; Fas: 0.12 ± 0.06; n = 3, p = 0.0002,
ANOVA with Dunnett post-hoc test), while the ROCK
inhibitor Y-27632 had no effect on α-Syn aggregation in
this assay (Y-27632: 0.95 ± 0.13, n = 3, p = 0.79, ANOVA
with Dunnett post-hoc test; Fig. 2a). It is worth noting that
the slope of the curve associated with elongation of the
fibril was steeper in the control and Y-27632 samples as
compared to Fasudil, suggesting that Fasudil not only
affects formation of aggregation seeds but also the elong-
ation of amyloid fibrils of α-Syn. The lack of defined amyl-
oid fibrils after 10 days of aggregation in the presence of
Fasudil was further corroborated by EM (Fig. 2b), as
opposed to the classical mature fibrillar structures formed
in the absence of Fasudil.
In order to obtain insight into the molecular nature of
the interaction between α-Syn and Fasudil, we took
Fig. 2 Fasudil delays the aggregation of α-Syn in solution through interaction with the α-Syn C-terminal domain. a ThT aggregation monitoring
of a 100 μM solution of α-Syn shows a longer nucleation phase and a smaller slope in presence of a 10:1 Fasudil to protein ratio. Data are given
as mean ± SD of at least three independent experiments, p < 0.001, ANOVA with Dunnett post-hoc test. Note that the ROCK inhibitor Y-27632 has
no effect on the aggregation kinetics even in the same concentration. b Electron micrographs show a decreased fibril formation after 10 days of
incubation in aggregation-prone conditions when Fasudil is present. Scale bars represent 200 nm. c Selected regions of 2D 15N-1H HSQC spectra
of α-Syn in the absence (black) and presence (red) of a 20:1 Fasudil to protein ratio. d Chemical shift perturbation plot of 15N/1H resonances of
α-Syn in the presence of increasing concentrations of Fasudil (Fasudil-to-α-Syn molar ratios are indicated). Note that the most affected amino acid
residues are in the C-terminal region, especially Y133 and Y136. e Structural representation of α-Syn and Fasudil’s interaction through the
C-terminal region (light blue), specifically in residues Y133 and Y136 (red). The N-terminal region of α-Syn is indicated in dark blue, the non-Aβ
component (NAC) domain is marked purple
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advantage of solution nuclear magnetic resonance
(NMR) analysis. NMR resonances are a reflection of the
microenvironment in which individual amino acids are
found and, therefore, are highly sensitive probes of pro-
tein-protein and/or protein-ligand interactions, allowing a
detailed description of interaction interfaces. Here, we
made use of two-dimensional 15N-1H HSQC experiments
in the presence of increasing amounts of Fasudil (Fig. 2c).
The perturbation in the relative position of signals in the
NMR spectra allowed us to determine that Fasudil prefer-
entially interacts with the C-terminal region of α-Syn,
especially with the aromatic residues Y133 and Y136, as
determined by the large chemical shift perturbation of
their NMR resonances (Fig. 2d). A structural represen-
tation of α-Syn and Fasudil’s interaction through the C-
terminal region, specifically in residues Y133 and Y136, is
given in Fig. 2e. The α-Syn model was taken from a
molecular dynamics simulation [46] with Fasudil placed
manually in the proximity of residues Y133 and Y136 with
the molecular visualization software VMD [24].
Effect of Fasudil on SynT aggregation is attenuated after
Y133/136A substitution
To address the influence of Y133 and Y136 on α-Syn
aggregation in the H4 cell culture model in vitro, both
residues were substituted with alanine in human synT
by site-directed mutagenesis, either as single (synT-Y133A
and synT-Y136A) or double mutant (synT-Y133,136A).
Number, size and distribution of inclusions in single H4
cells were not affected after transfection with the respect-
ive mutant synT as compared to wildtype (wt) synT
(Fig. 3a).
Again, treatment of H4 cells with 20 μM Fasudil signifi-
cantly reduced the number of transfected cells with inclu-
sions in case of wt synT (24.6 ± 1.93 % vs. 10.4 ± 2.37 %,
p = 0.007, T-Test), but had no significant effect on the
mutants synT-Y133A (34.7 ± 1.66 % vs. 25.6 ± 5.63 %),
synT-Y136A (33.7 ± 5.08 % vs. 21.0 ± 2.89 %), or the
double mutant synT-Y133A/Y136A (33.5 ± 4.44 % vs.23.8
± 3.20 %), indicating that synT aggregation can be impaired
by Fasudil via interaction with the C-terminal tyrosine
residues 133 and 136 (Fig. 3b).
Western blot analysis of synT, normalized to β-tubulin,
revealed that neither the single mutations synT-Y133A
(1.83 ± 0.08) and synT-Y136A (2.75 ± 0.72), nor the double
mutant synT-Y133/136A (2.27 ± 0.92) influenced synT
expression on the protein level as compared to wt synT
(0.98 ± 0.03) (data given as means ± SEM, n = 3 independ-
ent experiments, not significant, ANOVA) (Fig. 3c).
Effects of long-term treatment of α-SynA53T mice with
Fasudil
To investigate the influence of long-term Fasudil treat-
ment on α-Syn pathology in vivo we used a mouse
model expressing human α-SynA53T under the prion
protein (Prnp) promoter [16]. Homozygous α-SynA53T
mice develop a neuronal α-synucleinopathy with intra-
neuronal inclusions of α-Syn, triggering a severe move-
ment disorder beginning earliest at 8 months of age with
weight loss, followed by a paresis of the hind limbs, finally
leading to paralysis and death. In this study α-SynA53T
mice were treated with 10 or 30 mg/kg bw Fasudil from
day 50 on until death (Fig. 4a), and compared to untreated
Fig. 3 Substitution of Y133 and Y136 with alanine in synT blocks the aggregation-inhibiting effect of Fasudil. a H4 neuroglioma cells were treated
with 20 μM Fasudil or vehicle and transfected with wt synT or the indicated mutants together with SYPH1. 24 h post-transfection, cells were fixed
and immunostained against synT and SYPH1. Representative images show the expression of synT, SYPH1 and DAPI positive nuclei in the absence
of Fasudil. Scale bar 25 μm. b Transfected cells with and without inclusions from 9 images per experimental conditions of n = 4 independent
experiments were counted. Data are given as mean ± S.E.M, **p < 0.01, n.s. = not significant, T-Test. c Western blot analysis of H4 protein lysates
from wt or indicated mutants 24 h after transfection revealed no significant changes in synT protein expression
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α-SynA53T mice as well as wt littermate controls regarding
weight loss, motor and cognitive behavior.
α-SynA53T mice and wt controls were weighed weekly
to monitor for weight changes over the experimental
time course. Regarding their maximum weight, α-SynA53T
mice were insignificantly lighter (~33 g) than wt controls
(~35 g). After onset of clinical symptoms, α-SynA53T mice
rapidly lost weight as previously described [16], being
statistically significant at time of sacrifice as compared
to wt controls (wt ctrl: 34.0 ± 1.68 g; A53T ctrl: 26.7 ±
0.79 g, p = 0.003, T-Test; A53T Fas10: 27.7 ± 1.23 g;
A53T Fas30: 26.1 ± 1.29 g). Fasudil treatment did not
have any significant effect on the weight of α-SynA53T
mice (Fig. 4b, c).
Blood analysis did not show any significant differences
between Fasudil-treated and untreated animals. Leukocyte
(LEU) counts were detected between 3.1 and 9.0 × 103/μl,
erythrocytes (ERY) between 7.35 and 12.6 × 106/μl, and
thrombocytes (THR) ranged between 388 and 2102 × 103/
μl. Hemoglobin (HGB) ranged from 9.1 to 17.0 g/dl and
hematocrit (HCT) from 26.4 to 50.6 %. Biochemical ana-
lysis of renal and hepatic function parameters revealed
maximum values between 0.15 and 0.21 mg/dl of
creatinine (CREA), aspartate aminotransferase (AST) was
measured between 53 and 312 U/l, alanine aminotransfer-
ase (ALT) maximum values ranged between 18 and 113
U/l, and gamma-glutamyl transferase (GGT) was below
detection level of <4 U/l (Additional file 2: Figure S2).
Fig. 4 Fasudil treatment does not affect weight, rotarod performance or overall survival of α-SynA53T mice. a 50 days after birth (DOB = day of
birth) of α-SynA53T mice, Fasudil treatment with 10 mg/kg bw and 30 mg/kg bw was started. After 100 and 200 days, mice were tested on a
rotarod (Rot). From day 220 on, rotarod was performed twice a week to monitor for onset of clinical symptoms of α-SynA53T mice. b, c Weight
of α-SynA53T mice was monitored weekly. The last 10 weight measurements are displayed (b), as well as last weight at day of sacrifice (c). d, e
Rotarod analysis of α-SynA53T mice treated with 10 mg/kg bw and 30 mg/kg bw Fasudil as compared to untreated α-SynA53T controls and
wildtype controls. The last 10 rotarod performances before sacrifice are displayed for all animals in the respective treatment groups (d), as well
as the last rotarod performance before sacrifice, showing no significant differences between α-SynA53T mice with regard to Fasudil treatment
(e). f Survival of α-SynA53T mice treated with 10 mg/kg bw and 30 mg/kg bw Fasudil as compared to untreated α-SynA53T controls, showing no
significant differences between the groups. All data are given as means ± SEM; n(wt ctrl) = 10, n(A53T ctrl) = 10, n(A53T Fas10) = 10, n(A53T
Fas30) = 9; **p < 0.01, ***p < 0.001, n.s. = not significant; T-Test for comparisons between ctrl groups; ANOVA with Dunnett post-hoc test for
multiple group comparisons between α-SynA53T groups
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Rotarod performance of α-SynA53T mice is impaired with
disease onset
α-SynA53T mice and wt controls were pre-trained on the
rotarod to obtain a stable performance. Rotarod testing
after acute Fasudil treatment did not show any signifi-
cant effects (Additional file 3: Figure S3). Rotarod testing
at 100 and 200 days of age showed a stable performance
without any signs of impairment in α-SynA53T mice (data
not shown). Beginning from day 220 on, mice were
tested twice a week on the rotarod, to monitor motor
impairment as indication of onset of the clinical symp-
toms described for this model [16] (Fig. 4a). All mice
maintained a stable rotarod performance over time (Fig. 4d),
until with the onset of clinical symptoms α-SynA53T animals
displayed a massive rotarod failure as a clear marker for de-
clining motor function. Fasudil treatment did not improve
rotarod performance as compared to untreated α-SynA53T
mice. Figure 4e shows means ± SEM of last rotarod per-
formance before sacrifice (wt ctrl: 277 ± 8 s; A53T ctrl: 57 ±
13 s; A53T Fas10: 47 ± 10 s; A53T Fas30: 55 ± 14 s).
Survival of α-SynA53T mice is not altered by Fasudil
treatment
After the onset of clinical symptoms and when mice
undercut 50 % of the initial rotarod performance, mice
were assessed for abnormalities in gait (Catwalk gait ana-
lysis) and cognition (novel object recognition test). Due to
the fast progression of the disease in this particular model,
α-SynA53T mice were sacrificed after the last behavioral
test when hind limb paresis was present, to prevent ani-
mals from suffering. With regard to Fasudil treatment, no
significant differences in survival time between the groups
were detected (A53T ctrl: 509 ± 37 d; A53T Fas10:
428 ± 31 d; A53T Fas30: 523 ± 41 d) (Fig. 4f ).
Catwalk gait analysis reveals motor improvement after
Fasudil treatment
To detect more subtle differences in gait of α-SynA53T
mice after treatment with Fasudil, mice were tested with
the Catwalk gait analysis system, since this method is
more sensitive than the rotarod [62]. α-SynA53T mice
were tested after ‘disease onset’ as detected by rotarod
failure (Fig. 5a). Footprints of the mice were automat-
ically detected, and various gait parameters were ana-
lyzed (Fig. 5 b, c). Before disease onset at day 200, no
significant differences between the groups were apparent
(data not shown). Acute Fasudil treatment also did not
have any significant effects in the multiparametric gait
analysis (Additional file 4: Figure S4). After mice displayed
clinical symptoms, long-term Fasudil treatment signifi-
cantly improved gait performance of α-SynA53T mice as
compared to untreated controls. In detail, run average
speed was improved dose-dependently as compared to α-
SynA53T control, with high Fasudil dosage reaching
significance (wt ctrl: 28.6 ± 2.11 cm/s; A53T ctrl: 13.6 ±
1.20 cm/s, p = 7.05x10-6, T-test; A53T Fas10: 19.7 ±
1.85 cm/s; A53T Fas30: 21.7 ± 3.24 cm/s, p = 0.03,
ANOVA with Dunnett post-hoc test; Fig. 5d). Step
sequence regularity index (a fractional measure of inter-
paw coordination) was significantly improved dose-
dependently after Fasudil treatment (wt ctrl: 95.0 ±
2.13 %; A53T ctrl: 45.5 ± 13.59 %, p = 0.004, T-test;
A53T Fas10: 83.9 ± 10.74 %, p = 0.03; A53T Fas30:
93.7 ± 2.10 %, p = 0.006, ANOVA with Dunnett post-
hoc test; Fig. 5e). Print area, swing speed, stride length
as well as print positions (distance between the pos-
ition of the hind paw and the position of the previ-
ously placed front paw on the same side of the body
and in the same step cycle) were significantly im-
proved by high Fasudil treatment. As examples only
right paws are displayed: right front (RF) print area was al-
most rescued as compared to controls (wt ctrl: 0.22 ±
0.03 cm2; A53T ctrl: 0.06 ± 0.02 cm2, p = 0.0003, T-test;
A53T Fas10: 0.12 ± 0.03 cm2; A53T Fas30: 0.20 ±
0.05 cm2, p = 0.023, ANOVA with Dunnett post-hoc test;
Fig. 5f), same effect was seen for right hind (RH) print
area (wt ctrl: 0.28 ± 0.05 cm2; A53T ctrl: 0.03 ± 0.01 cm2,
p = 0.0003, T-test; A53T Fas10: 0.16 ± 0.04 cm2; A53T
Fas30: 0.25 ± 0.06 cm2, p = 0.009, ANOVA with Dunnett
post-hoc test; Fig. 5i). Swing speed of the right front
leg was significantly improved (wt ctrl: 64.9 ± 4.81 cm/
s; A53T ctrl: 33.3 ± 3.80 cm/s, p = 4.2x10-5, T-test; A53T
Fas10: 44.3 ± 3.04 cm/s; A53T Fas30: 48.3 ± 5.28 cm/s, p
= 0.03, ANOVA with Dunnett post-hoc test; Fig. 5g),
as was the swing speed for the right hind leg (wt ctrl:
72.5 ± 3.64 cm/s; A53T ctrl: 35.9 ± 5.53 cm/s, p = 0.0002, T-
test; A53T Fas10: 48.6 ± 5.03 cm/s; A53T Fas30: 62.4 ±
7.61 cm/s, p = 0.014, ANOVA with Dunnett post-hoc test;
Fig. 5j). Print positions of the right paws were significantly
improved after high Fasudil treatment (wt ctrl: 0.97 ±
0.13 cm; A53T ctrl: 1.80 ± 0.27 cm, p = 0.019, T-test; A53T
Fas10: 1.10 ± 0.16 cm, p = 0.06; A53T Fas30: 0.73 ± 0.23 cm,
p = 0.005, ANOVA with Dunnett post-hoc test; Fig. 5h).
Stride length of the right hind leg was significantly im-
proved after Fasudil treatment as compared to un-
treated control (wt ctrl: 6.9 ± 0.21 cm; A53T ctrl: 4.9 ±
0.27 cm, p = 6.2x10-5, T-test; A53T Fas10: 6.2 ± 0.23 cm,
p = 0.005; A53T Fas30: 6.0 ± 0.26 cm, p = 0.009, ANOVA
with Dunnett post-hoc test; Fig. 5k). Taken together,
Catwalk analysis revealed a dose-dependent, significant
improvement of several gait parameters of α-SynA53T
mice treated with Fasudil in a dose-dependent manner
as compared to untreated α-SynA53T controls.
NOR test shows rescue of cognitive impairment after
Fasudil treatment
To test if Fasudil treatment influences cognition in α-
SynA53T mice, the NOR-test was performed. Parameters
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of general activity (mobility, distance moved, mean
velocity) were recorded, and the discrimination ratio
between interaction with novel and familiar object was
calculated as described before [6]. Before the first signs
of clinical symptoms, mice were tested on day 200.
Discrimination ratio showed no significant differences
between the treatment groups at this time point (wt ctrl:
0.58 ± 0.05; A53T ctrl: 0.59 ± 0.05; A53T Fas10: 0.52 ±
Fig. 5 Catwalk gait analysis shows improved gait performance after Fasudil treatment in α-SynA53T mice. a α-SynA53T mice were treated with Fasudil at
10 mg/kg bw and 30 mg/kg bw starting at day 50 (DOB = day of birth). Catwalk gait analysis was performed after 200 days, and after the mouse
showed clinical symptoms of the disease by impaired rotarod performance. b Footprints of mice were automatically detected by the Noldus Catwalk
XT gait analysis system (RF = right front, LF = left front, RH = right hind, LH = left hind). c Different gait parameters like stand (duration in seconds of
contact of a paw with the glass plate), swing (duration in seconds of no contact of a paw with the glass plate), step cycle, stride length, print area, print
length and print width were analyzed. d-k Run average speed (d), step sequence regularity index as a fractional measure of inter-paw coordination
(e), RF and RH print area (f, i), RF and RH swing speed (g, j), print positions of the right paws (h) and RH stride length (k) were significantly improved
after Fasudil treatment as compared to untreated α-SynA53T controls. All data given as means ± SEM; n(wt ctrl) = 10, n(A53T ctrl) = 10,
n(A53T Fas10) = 10, n(A53T Fas30) = 9; *p < 0.05, **p < 0.01, ***p < 0.001, §p = 0.06, n.s. = not significant; T-Test for comparisons between
ctrl groups; ANOVA with Dunnett post-hoc test for multiple group comparisons between α-SynA53T groups
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0.04 d; A53T Fas30: 0.58 ± 0.07), neither did mobility (wt
ctrl: 167 ± 18 s; A53T ctrl: 202 ± 15 s; A53T Fas10: 200 ±
9 s; A53T Fas30: 160 ± 14 s), moved distance (wt ctrl:
1117 ± 166 cm; A53T ctrl: 1677 ± 121 cm; A53T Fas10:
2146 ± 239 cm; A53T Fas30: 1850 ± 381 cm), and mean
velocity (wt ctrl: 4.6 ± 0.69 cm/s; A53T ctrl: 5.7 ±
0.41 cm/s; A53T Fas10: 7.8 ± 0.77 cm/s; A53T Fas30:
6.2 ± 1.25 cm/s).
After the appearance of first clinical symptoms indicated
by rotarod failure, mice were tested again in the NOR-test.
Here, α-SynA53T ctrl mice showed a marked impairment
in cognitive function compared to wt littermates, which
was significantly reverted by Fasudil treatment (wt
ctrl: 0.53 ± 0.09; A53T ctrl: 0.28 ± 0.08; p = 0.03, T-Test;
A53T Fas10: 0.61 ± 0.06; A53T Fas30: 0.58 ± 0.05; p = 0.003,
p = 0.010, ANOVA with Dunnett post-hoc test as compared
to A53T ctrl) (Fig. 6c). Mobility time (wt ctrl: 139 ± 13 s;
A53T ctrl: 113 ± 21 s; A53T Fas10: 129 ± 21 s; A53T Fas30:
116 ± 11 s), moved distance (wt ctrl: 1346 ± 214 cm; A53T
ctrl: 1489 ± 249 cm; A53T Fas10: 1491 ± 216 cm; A53T
Fas30: 1582 ± 175 cm) (Fig. 6d), as well as mean velocity
(wt ctrl: 4.5 ± 0.71 cm/s; A53T ctrl: 5.0 ± 0.83 cm/s; A53T
Fas10: 5.1 ± 0.73 cm/s; A53T Fas30: 5.3 ± 0.58 cm/s) were
not significantly different between the groups.
Analysis of α-SynA53T brain tissue depicts alterations in α-
Syn pathology
To investigate the effect of Fasudil treatment on histopath-
ology in the brain of α-SynA53T mice, an immunohisto-
chemical analysis was performed after 200 days as well as
after disease onset (Fig. 7a). Cells showing α-Syn aggregates
after proteinase-K digestion were quantified in three
different brain regions, namely red nucleus (RN), substantia
nigra pars compacta (SN) and dorsal raphe nucleus (DR),
and compared between the different treatment groups and
wt littermate controls. After 200 days no proteinase-K
resistant α-Syn aggregates could be detected in α-SynA53T
mice (data not shown). As expected, no α-Syn pathology
was detected in the wt controls, whereas at disease-
onset α-SynA53T mice showed α-Syn aggregates in all in-
vestigated brain regions. Interestingly, Fasudil treatment
significantly decreased the number of cells showing α-Syn
aggregates.
In the RN, cells with α-Syn aggregates were reduced
by about 40 % (A53T Fas10: 9.68 ± 1.42 cells/1 M
px2, p = 0.045; A53T Fas30: 9.32 ± 2.45 cells/1 M px2,
p = 0.034, ANOVA with Dunnett post-hoc test, Fig. 7b)
as compared to vehicle-treated α-SynA53T mice (A53T
ctrl: 16.04 ± 1.54 cells/1 M px2). Importantly, the
evaluation of total neuronal numbers by NeuN-staining in
the RN did not reveal any significant differences between
the treatment groups (wt ctrl: 22.97 ± 2.37 cells/1 M px2,
A53T ctrl: 29.22 ± 1.70 cells/1 M px2, A53T Fas10: 23.07
± 2.99 cells/1 M px2, A53T Fas30: 27.64 ± 1.08 cells/1 M
px2, n.s., ANOVA, Fig. 7b).
In the SN the Fasudil treatment reduced cells with α-
Syn aggregates by more than 70 % as compared to
vehicle-treated animals (A53T ctrl: 1.60 ± 0.28 cells/1 M
px2; A53T Fas10: 0.41 ± 0.13 cells/1 M px2, p = 0.014;
A53T Fas30: 0.50 ± 0.34 cells/1 M px2, p = 0.019,
ANOVA with Dunnett post-hoc test, Fig. 7c). The evalu-
ation of absolute TH-positive cell numbers in the SN did
not show any significant differences between the treat-
ment groups (wt ctrl: 42.01 ± 1.83 cells/1 M px2, A53T
Fig. 6 Fasudil treatment improves recognition memory of α-SynA53T mice. a α-SynA53T mice were treated with Fasudil at 10 mg/kg bw and
30 mg/kg bw starting at day 50 (DOB = day of birth). Novel object recognition test (NOR) was performed after 200 days, and after the mouse
showed clinical symptoms of the disease by impaired rotarod performance. b Mice were videotaped in an arena with a familiar (F) and a novel
(N) object. The time each mouse was heading the objects in the respective zone of interaction (ZOI) was recorded. General activity was tracked
simultaneously. c, d The discrimination ratio (c) and distance moved (d) are displayed for the respective treatment groups as compared
to controls after disease onset (n(wt ctrl) = 7, n(A53T ctrl) = 8, n(A53T Fas10) = 10, n(A53T Fas30) = 9). Data are displayed as means ± SEM; *p < 0.05,
**p < 0.01; T-Test for comparisons between ctrl groups; ANOVA with Dunnett post-hoc test for multiple group comparisons between α-SynA53T groups
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ctrl: 46.21 ± 2.72 cells/1 M px2, A53T Fas10: 46.11 ± 7.25
cells/1 M px2, A53T Fas30: 45.43 ± 7.57 cells/1 M px2,
n.s., ANOVA, Fig. 7c).
Fasudil treatment lead also to a reduction of cells bearing
α-Syn aggregates in the DR by more than 50 % as com-
pared to vehicle-treated controls (A53T: 2.22 ± 0.28 cells/
Fig. 7 Fasudil treatment reduces the number of cells with α-Syn-aggregates without altering neuronal numbers in the midbrain of α-SynA53T mice.
a. Immunohistochemical staining against proteinase-K resistant α-Syn aggregates, as well as NeuN, TH and TPH2 in combination with nuclear staining
(DAPI) was performed to investigate the effect of Fasudil on α-Syn pathology in α-SynA53T mice after disease onset. Treatment groups were wildtype
control (wt ctrl), α-SynA53T control (A53T ctrl), α-SynA53T with 10 mg/kg bw Fasudil (A53T Fas10) and α-SynA53T with 30 mg/kg bw Fasudil (A53T Fas30).
b. Immunohistochemical analysis of red nucleus (RN; n(wt ctrl) = 5, n(A53T ctrl) = 7, n(A53T Fas10) = 6, n(A53T Fas30) = 6 for α-Syn aggregates; n(wt
ctrl) = 6, n(A53T ctrl) = 6, n(A53T Fas10) = 6, n(A53T Fas30) = 6 for NeuN. c. Immunohistochemical analysis of substantia nigra (SN; n(wt ctrl) = 5,
n(A53T ctrl) = 8, n(A53T Fas10) = 8, n(A53T Fas30) = 9 for α-Syn aggregates; n(wt ctrl) = 5, n(A53T ctrl) = 6, n(A53T Fas10) = 6, n(A53T Fas30) = 6
for TH. d Immunohistochemical analysis of the dorsal raphe nucleus (DR; n(wt ctrl) = 4, n(A53T ctrl) = 4, n(A53T Fas10) = 9, n(A53T Fas30) = 5 for
α-Syn aggregates; n(wt ctrl) = 4, n(A53T ctrl) = 4, n(A53T Fas10) = 9, n(A53T Fas30) = 5 for TH. Drawings on the left show localization of
respective brain regions, exemplary pictures in the middle show cells from respective brain regions with proteinase-K resistant α-Syn
aggregates, as well as NeuN, TH, TPH2 and DAPI positive cells in brains of untreated α-SynA53T mice. Data on the right are presented as
means ± SEM; * p <0.05; ** p < 0.01; *** p < 0.001; n.s. = not significant; T-Test for comparisons between untreated groups; ANOVA with
Dunnett post-hoc test for multiple group comparisons between α-SynA53T groups; 1M px2 = one million square pixels. Scale bar = 20 μm
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1 M px2; A53T Fas10: 1.22 ± 0.13 cells/1 M px2, p = 0.009;
A53T Fas30: 0.90 ± 0.27 cells/1 M px2, p = 0.002, ANOVA
with Dunnett post-hoc test, Fig. 7d). The evaluation of total
TPH2-positive cells in the DR did not reveal any significant
differences (wt ctrl: 12.25 ± 1.12 cells/1 M px2; A53T ctrl:
12.43 ± 1.91 cells/1 M px2; A53T Fas10: 11.65 ± 0.88 cells/
1 M px2; A53T Fas30: 12.03 ± 2.11 cells/1 M px2, n.s.,
ANOVA, Fig. 7d).
Discussion
α-Syn aggregation is a major pathophysiological step in
the development of PD. Since its discovery [41] and
consequent identification as most abundant protein
component in Lewy bodies [53], α-Syn was shown to be
involved in numerous cellular processes [4, 14, 29, 66].
Therapeutic approaches addressing the aggregation of α-
Syn thus hold the promise to result in true disease-
modification and attenuate progression in PD.
Recently, ROCK was characterized as promising new
molecular therapeutic target. Its pharmacological inhib-
ition resulted in prevention of neurodegeneration, fos-
tered axonal regeneration and beneficially regulated
microglial dysfunction in models of PD and other neuro-
degenerative disorders [3, 8, 26, 27, 50, 58–61, 63]. Here,
we evaluated the anti-aggregative potential of pharmaco-
logical ROCK inhibition using Fasudil, which is already
approved for clinical use in humans [44].
In contrast to the structurally unrelated 4-aminopyridine
derivative Y-27632, Fasudil treatment significantly reduced
the number of H4 cells with SYPH1/synT inclusions in
vitro, which was confirmed by SEC-HPLC followed by dot-
blot analysis. To understand the molecular basis of
this reduced aggregate formation, we performed a
cell-free thioflavin-T aggregation assay. Interestingly,
again in contrast to Y-27632, Fasudil significantly
delayed α-Syn aggregation, which was affirmed by
electron microscopy and indicated a direct inhibiting
function of Fasudil on α-Syn aggregation. Since this
effect was observed in a cell-free assay, it was not
mediated by the ROCK-inhibiting properties of Fasu-
dil. NMR spectroscopy revealed a direct binding of
Fasudil to two tyrosine residues in the C-terminal
region of α-Syn, namely Y133 and Y136, and site-
directed mutagenesis of these residues confirmed the
biological relevance of this interaction in the H4
aggregation model in vitro. The C-terminal region
was recently shown to be involved in α-Syn fibrilliza-
tion [25], with C-terminal truncation accelerating the
ability of α-Syn to form fibrils in vitro [32] and in
vivo [35, 37], whereas negative charge in the C-
terminus of full-length α-Syn delayed fibril formation
[23, 25]. Interestingly, Izawa and colleagues suggested
Y136 as critical element in promoting fibril formation
[25]. Our data now show that Fasudil binds to
precisely this particular C-terminal tyrosine. This data
prompted us to assess the effects of Fasudil treatment
in an in vivo-model of α-Syn aggregation.
The influence of long-term Fasudil treatment on α-Syn
pathology in vivo was investigated in the α-SynA53T
mouse model [16], corresponding to a mutation found
in a familial form of PD [47]. Animals were treated with
Fasudil from day 50 on until death, and no acute Fasudil
effects with regard to motor behavior were detected.
The average survival time of α-SynA53T mice with high
Fasudil treatment was more than 500 days, and did not
differ significantly from untreated α-SynA53T mice. Fasudil
has already been used in animal models of neurodegenera-
tion and was well tolerated in treatment paradigms for up
to four months [58–60]. Here we present the first long-
term animal study supporting the favorable safety profile
of Fasudil over more than 15 months average treatment
time, without any obvious unwanted side effects. Import-
antly, blood analysis revealed no significant changes after
Fasudil treatment, with all parameters being in the normal
range for laboratory mice [7, 9, 11, 49]. Disease onset
could be clearly determined by rotarod failure, which is in
line with previous findings [16]. No rotarod failure of α-
SynA53T mice was detected before disease onset, although
recent studies report contradictory findings in the same
model [19, 45, 68].
To further investigate motor performance, the Catwalk
gait analysis system was used. In contrast to the rotarod,
here the animals walk freely and are not forced due to
an automated treadmill, which allows a highly sensitive
detection of subtle gait changes [62]. α-SynA53T mice
showed a massive decline in stride length and velocity at
disease onset, which could be translated to gait deficits
observed in PD patients [33, 54] and is in line with
previous findings in this model [17, 45]. Interestingly, we
show that numerous gait parameters were significantly
improved by long-term Fasudil treatment in a dose-
dependent manner.
Since Fasudil attenuated aggregation of α-Syn in vitro, we
analyzed whether its application in the α-SynA53T mouse
model also results in a histological improvement in vivo.
After 200 days no α-Syn pathology could be detected in α-
SynA53T mice, which is in line with previous findings in this
model [16]. Remarkably, the amount of neurons in the RN
and SN showing α-Syn pathology after proteinase-K diges-
tion at disease-onset was significantly decreased after
Fasudil treatment, whereas the number of NeuN-positive
cells in the RN was not affected. The number of TH-
positive cells in the SN was also not affected, which is in
line with previous findings showing that TH neurons in the
SN of α-SynA53T mice do not display the same selective
vulnerability as in humans [16]. Since RN and SN are
highly involved in motor function and coordination in
rodents, increased α-Syn pathology in these regions was
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suggested to compromise their function and thus contrib-
ute to the motor deficits [16]. We hypothesize that specific
binding of Fasudil to α-Syn, as demonstrated by NMR
analysis, contributes to the reduction of α-Syn pathology in
RN and SN, thereby improving fine motor function.
In addition to motor deficits, PD patients show
numerous non-motor symptoms, including cognitive
decline [5, 10]. We therefore analyzed the presence of
cognitive impairments and the putative therapeutic
effect of Fasudil in α-SynA53T mice. The NOR-test has
been extensively used to detect cognitive deficits in
numerous disease models [6, 20, 39]. In contrast to a
previous study in a synucleinopathy mouse model [40],
we did not detect any significant differences in cognitive
behavior after 200 days in our α-SynA53T mice. However,
at onset of motor symptoms there was a significant
alteration in the novelty seeking behavior, which was
reversed by Fasudil treatment. This is in line with previ-
ous findings showing significant deficits in short term
memory in this mouse line, postulated to be mediated
by a dysfunctional dopamine system [36, 45, 51, 67]. In
addition to dopaminergic projections, other neurotrans-
mitter systems are known to contribute to motor and
particularly non-motor symptoms in PD. For example,
the serotonergic system is involved in memory function
in PD [21]. The reduction of α-Syn pathology in the DR
together with the recovery of recognition memory by
Fasudil suggests that drugs acting in a disease-modifying
manner by modification of α-Syn aggregation may also
successfully target non-motor symptoms induced by
non-dopaminergic pathology.
In regard to transfer of these findings into clinical
trials, Fasudil has a highly promising translational poten-
tial, as it is already approved for clinical use in humans
in Japan, showing a very favorable safety profile [44].
Fasudil is active after oral administration and is capable
of crossing the blood–brain-barrier [56, 60]. Although
other pharmacological ROCK inhibitors, e.g. Y-27632,
are more selective towards ROCK, the latter compound
did not affect α-Syn aggregation. Interestingly, Y-27632
was shown to improve degradation of mutant huntingtin
as well as motor performance in the R6/2 mouse model
of Huntington’s disease [34]. Besides, the effect of
NSAIDs on lowering the amount of Aβ42 in models of
Alzheimer’s disease is mediated by ROCK inhibition and
can be mimicked by Y-27632 [69]. Thus, in addition to
the specific anti-aggregative effect of Fasudil through
direct molecular interaction with α-Syn, ROCK inhib-
ition may also contribute to a depletion of aggregation-
prone proteins. Increased levels of ROCK were also
recently discovered in brains of patients with progressive
supranuclear palsy and corticobasal degeneration, and
ROCK inhibition attenuated tau pathology in Drosophila
[15]. Thus, different lines of evidence suggest that ROCK
is involved in the pathogenesis of aggregation disorders
and that ROCK inhibition represents a promising thera-
peutic strategy [50, 58–61].
Here we describe for the first time to our knowledge
the anti-aggregative potential of the ROCK-inhibitor
Fasudil via direct binding to α-Syn, which suggests a
new treatment approach employing a double function of
Fasudil. Although in recent years a number of α-Syn ag-
gregation inhibitors have been described [1, 13, 55, 57],
most of them are “pan-assay interference compounds” with
a questionable clinical perspective [2]. High-throughput
screening revealed more specific compounds like the α-
Syn-oligomer-binding Anle-138b [65] or recently discov-
ered monomeric α-Syn-binding BIOD303 [43], appearing
more auspicious. One of the major obstacles of these
new compounds, however, is the so far missing ap-
proval for human treatment with largely unclear safety
and tolerability issues. Since Fasudil is already approved
for clinical human treatment, the repurposing of this
drug for the treatment of PD and other synucleinopa-
thies appears therefore highly promising.
Conclusion
We describe here the anti-aggregative potential of the
ROCK-inhibitor Fasudil via direct binding to α-Syn,
which opens a new treatment avenue employing a
ROCK-independent function of Fasudil in PD and other
synucleinopathies. This is of particular interest, as Fasu-
dil is already licensed in Japan for the treatment of sub-
arachnoid haemorrhage-induced vasospasms and has
been widely used with a beneficial safety profile. Since
disease-modifying therapies for neurodegenerative dis-
eases are urgently needed, the translation of our findings
into a clinical pilot study appears realistic in the near
future.
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Additional files
Additional file 1: Figure S1. Y-27632 treatment has no effect on synT
aggregation in H4 cells in vitro. a H4 neuroglioma cells were seeded in
the presence or absence of Y-27632 and 24 h later transfected with
plasmids encoding for synT and SYPH1. 24 h after transfection, cultures
were investigated by immunocytochemistry (ICC). b ICC of synT and
SYPH1 in H4 cells 24 h after transfection, treated with 5 or 20 μM
Y-27632. Scale bar: 50 μm. c Quantification of transfected H4 cells with
inclusions 24 h after transfection and treatment with different Y-27632
concentrations. n.s. = not significant, ANOVA, n = 3. Data are given as
mean ± SEM, n.s. = not significant, ANOVA. (TIF 723 kb)
Additional file 2: Figure S2. Blood cell counts and biochemical
analysis of renal and hepatic function parameters in α-SynA53T mice. a
Leucocytes (LEU). b Erythrocytes (ERY). c Thrombocytes (THR). d
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Hemoglobin (HGB). e Hematocrit (HCT). f Creatinine (CREA). g Alanine
aminotransferase (ALT). h Aspartate aminotransferase (AST). i gamma-glutamyl
transferase (GGT, # = all values below detection level). All measured parameters
were in the normal range for laboratory mice. a-e: n(wt ctrl) = 5,
n(A53T ctrl) = 2, n(A53T Fas10) = 4, n(A53T Fas30) = 5; f-i: n(wt ctrl) = 5,
n(A53T ctrl) = 1, n(A53T Fas10) = 8, n(A53T Fas30) = 7. (TIF 125 kb)
Additional file 3: Figure S3. Acute Fasudil treatment does not affect
rotarod performance of α-SynA53T mice. a α-SynA53T mice were tested on
the rotarod before Fasudil treatment with 30 mg/kg bw for 24 h via the
drinking water, as well as directly after treatment. b α-SynA53T mice were
tested on the rotarod 24 h before Fasudil treatment with 20 mg/kg bw
via oral gavage. 30 min after application mice were tested again on the
rotarod. c No significant differences were detected after Fasudil treatment
for 24 h via the drinking water as compared to controls. Data are given
as means ± SEM; n(A53T ctrl) = 7, n(A53T Fas) = 7; n.s. = not significant;
T-Test. d No significant differences were detected 30 min after Fasudil
treatment via oral gavage as compared to controls. Data are given as
means ± SEM; n(A53T ctrl) = 9, n(A53T Fas) = 9; n.s. = not significant; T-Test.
(TIF 176 kb)
Additional file 4: Figure S4. Acute Fasudil treatment does not affect
Catwalk performance of α-SynA53T mice. a α-SynA53T mice were tested on
the Catwalk before Fasudil treatment with 30 mg/kg bw for 24 h via the
drinking water, as well as directly after treatment. b α-SynA53T mice were
tested on the Catwalk 24 h before Fasudil treatment with 20 mg/kg bw
via oral gavage. 30 min after application mice were tested again on the
Catwalk. c, e, g, i No significant differences were detected after Fasudil
treatment for 24 h via the drinking water as compared to controls
regarding run average speed (c), RH print area (e), RH swing speed (g),
and RH stride length (i). Data are given as means ± SEM; n(A53T ctrl) = 7,
n(A53T Fas) = 7; n.s. = not significant; T-Test. d, f, h, j No significant
differences were detected 30 min after Fasudil treatment via oral gavage
as compared to controls regarding run average speed (d), RH print
area (f), RH swing speed (h), and RH stride length (j). Data are given
as means ± SEM; n(A53T ctrl) = 9, n(A53T Fas) = 9; n.s. = not significant;
T-Test. (TIF 435 kb)
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